Patients with score level 6 in our study were 18.7% compared to the 25.8% in Stockwin et al., however, Stockwin et al.  performed IHC staining with mTOR and phospho-mTOR (p-mTOR) on multiple myeloma BMB sections, but in our study, we studied only the mTOR [30]. So, this may reflect a relative higher expression of the marker in their study. This evidence concerns the gene MTOR and AL amyloidosis.